Incidence, Risk Factor, Treatment and Overall Survival of Locally Recurrent Rectal Cancer
NCT05475301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1431
Last updated 2023-11-18
Summary
Data on disease recurrence was collected for all primary rectal cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locally recurrent rectal cancer were determined.
Conditions
- Rectal Neoplasms
- Neoplasm Recurrence, Local
Sponsors & Collaborators
-
Radboud University Medical Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-01
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
More Related Trials
-
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
NCT00004193 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer
NCT03127007 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
NCT01333709 ·Status: COMPLETED ·Phase: PHASE2
-
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
NCT06678919 ·Status: RECRUITING
-
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
NCT00975897 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials
NCT03350412 ·Status: UNKNOWN
-
The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment
NCT05655780 ·Status: RECRUITING
-
Stage II/III Colorectal Cancer Recurrence
NCT06314958 ·Status: RECRUITING
-
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00005085 ·Status: COMPLETED ·Phase: PHASE2
-
Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
NCT01082757 ·Status: COMPLETED
-
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
NCT00005833 ·Status: COMPLETED ·Phase: PHASE2
-
Individual Following in Anal Cancer With PET/CT
NCT02697084 ·Status: UNKNOWN
-
A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer
NCT01148758 ·Status: COMPLETED ·Phase: PHASE1
-
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
NCT04050345 ·Status: RECRUITING
-
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
NCT00551213 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
NCT01453257 ·Status: COMPLETED ·Phase: PHASE2
-
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NCT00856375 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
NCT00717990 ·Status: TERMINATED ·Phase: PHASE2
-
Synergism of Immunomodulation and Tumor Ablation
NCT03101475 ·Status: COMPLETED ·Phase: PHASE2
-
Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma
NCT00312000 ·Status: COMPLETED ·Phase: PHASE3
-
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00032110 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan in Treating Patients With Colorectal Cancer
NCT00003843 ·Status: TERMINATED
-
Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
NCT00506571 ·Status: UNKNOWN ·Phase: PHASE2
-
Rosuvastatin in the Treatment of Rectal Cancer
NCT02569645 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
NCT00755534 ·Status: TERMINATED ·Phase: PHASE2